Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus

Monday, August 14, 2017 1 min read

Key Takeaway: Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus

Full Press Release Details

Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus.